TZ20

Tirzepatide is a synthetic peptide designed as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique mechanism of action distinguishes it from traditional GLP-1 receptor agonists, offering a synergistic approach to enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. Researchers utilize Tirzepatide in studies investigating its potential in metabolic disorders, including type 2 diabetes and obesity, as well as exploring its broader impact on cardiovascular health, non-alcoholic fatty liver disease (NAFLD), and neurological functions related to appetite control. For optimal research outcomes, Tirzepatide should be handled with care in a controlled laboratory environment. It is supplied as a lyophilized powder and should be reconstituted according to specific experimental protocols, typically with sterile, deionized water or an appropriate buffer. Avoid repeated freeze-thaw cycles, which can degrade the peptide's integrity. Researchers should adhere to standard laboratory safety procedures, including wearing appropriate personal protective equipment (PPE) such as gloves and eye protection, when handling this compound. Storage of Tirzepatide is critical to maintain its stability and biological activity. The lyophilized powder should be stored long-term at -20°C or below, protected from light and moisture. Once reconstituted, solutions should be used immediately or stored at 2-8°C for short periods (e.g., 24-48 hours), depending on the solvent and concentration, while minimizing light exposure. For longer-term storage of reconstituted solutions, aliquoting and freezing at -20°C or below is recommended, though repeated freeze-thaw cycles should still be avoided.